Early subcutaneous administration of IFNβ in combination with lopinavir/ritonavir and ribavirin in patients with mild to moderate COVID-19 led to a significant reduction of symptoms, shortening the duration of viral shedding and hospital stay (23). Here, IFNB1 is linked to COVID-19.